Development and external validation of a nomogram for individualized adjuvant imatinib duration for high‐risk gastrointestinal stromal tumors: A multicenter retrospective cohort study

Abstract Introduction The main emphasis of the research about adjuvant imatinib for high‐risk gastrointestinal stromal tumors (GISTs) is prolonging the treatment duration and ignores the heterogeneous that 10‐year recurrence rates ranged from about 20%–100%. Thus, this study evaluated the effect of...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Ruolin Liu, Yingxin Wu, Jin Gong, Rui Zhao, Li Li, Qianyi Wan, Nan Lian, Xiaoding Shen, Lin Xia, Yuhou Shen, Haitao Xiao, Xiaoting Wu, Yi Chen, Ying Cen, Xuewen Xu
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Wiley 2022-08-01
Σειρά:	Cancer Medicine
Θέματα:	adjuvant imatinib gastrointestinal stromal tumors high risk individualized treatment duration
Διαθέσιμο Online:	https://doi.org/10.1002/cam4.4673
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!